Conduit Pharmaceuticals Inc. (CDT)vsVertex Pharmaceuticals Inc (VRTX)
CDT
Conduit Pharmaceuticals Inc.
$0.74
-13.41%
HEALTHCARE · Cap: $3.91M
VRTX
Vertex Pharmaceuticals Inc
$446.83
+1.24%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
CDT
Avoid17
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CDT.
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Grey zone — moderate risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CDT
CDT has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : CDT
The primary concerns for CDT are Revenue Growth, EPS Growth, Altman Z-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CDT profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
CDT carries more volatility with a beta of 1.57 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 17/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Conduit Pharmaceuticals Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Conduit Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for oncology and rare diseases, targeting substantial unmet medical needs in these critical areas. Utilizing its proprietary drug delivery technology, Conduit aims to enhance the effectiveness and safety of established treatments, thereby improving patient outcomes while reducing side effects. With a seasoned management team and a commitment to forming strategic alliances, the company is well-positioned to propel its innovative product pipeline forward and make a significant impact on the healthcare industry.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?